Detomidine

Verify with FDA CVM →

160 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
160
Total Reports
11
Deaths Reported
690.0%
Death Rate

Active Ingredients

Detomidine

Administration Routes

IntravenousUnknownSublingualPeriodontalOralIntramuscularTopicalSubcutaneousIntra-Arterial

Species Affected

Horse 136
Unknown 8
Dog 7
Human 5
Donkey 3
Cat 1

Most Affected Breeds

Horse (unknown) 34
Quarter Horse 33
Unknown 13
Thoroughbred 10
Arab 7
Paint 6
Horse (other) 5
Tennessee Walking Horse 5
Mixed (Horse) 4
Crossbred Equine/horse 4

Most Reported Reactions

INEFFECTIVE, SEDATION 32
Sedation prolonged 19
Tachypnoea 15
Accidental exposure 13
Ataxia 12
Tachycardia 11
Recumbency 10
Lack of efficacy - NOS 8
Bradycardia 8
Elevated creatinine 8
Collapse (see also 'Cardio-vascular' and 'Systemic disorders') 8
Hyperhidrosis 7

Outcome Breakdown

Recovered/Normal
38 (54.3%)
Outcome Unknown
17 (24.3%)
Euthanized
6 (8.6%)
Died
5 (7.1%)
Ongoing
3 (4.3%)
Recovered with Sequela
1 (1.4%)

Data Summary

Metric Value
Total adverse event reports 160
Reports involving death 11
Case-fatality rate (reported events) 690.0%
Distinct species in reports 6
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Detomidine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 160 adverse event reports referencing Detomidine, including 11 reports in which the animal died — a 690.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Detomidine. Reported administration routes include Intravenous, Unknown, Sublingual, Periodontal. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Detomidine reports are Horse (136 reports), Unknown (8 reports), Dog (7 reports), with Horse accounting for the largest share. Within those species, Horse (unknown) (34), Quarter Horse (33), Unknown (13) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Detomidine are INEFFECTIVE, SEDATION (32), Sedation prolonged (19), Tachypnoea (15), Accidental exposure (13). Of the 70 reports with a coded outcome, Recovered/Normal is the leading category at 54.3%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Detomidine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial